Clinical Trials & Research Studies Near You (Updated 4/25)

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

NCT06577441

Recruiting

This phase II MyeloMATCH treatment trial compares the usual treatment of cedazuridine-decitabine (ASTX727) to the combination treatment of ASTX727 and enasidenib in treating patients with higher-risk, IDH2-mutated myelodysplastic syndrome (MDS). ASTX727 is a combination of two drugs, decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/22/2025

Locations: Illinois CancerCare-Bloomington, Bloomington, Illinois +32 locations

Illinois CancerCare-Bloomington, Bloomington, Illinois

Illinois CancerCare-Canton, Canton, Illinois

Illinois CancerCare-Carthage, Carthage, Illinois

Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Illinois CancerCare-Dixon, Dixon, Illinois

Crossroads Cancer Center, Effingham, Illinois

Illinois CancerCare-Eureka, Eureka, Illinois

Illinois CancerCare-Galesburg, Galesburg, Illinois

Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois

Illinois CancerCare-Macomb, Macomb, Illinois

Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois

Illinois CancerCare-Pekin, Pekin, Illinois

Illinois CancerCare-Peoria, Peoria, Illinois

Illinois CancerCare-Peru, Peru, Illinois

Illinois CancerCare-Princeton, Princeton, Illinois

Illinois CancerCare - Washington, Washington, Illinois

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan

Cancer Hematology Centers - Flint, Flint, Michigan

Genesee Hematology Oncology PC, Flint, Michigan

Genesys Hurley Cancer Institute, Flint, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan

Parkland Health Center - Farmington, Farmington, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri

Missouri Baptist Sullivan Hospital, Sullivan, Missouri

BJC Outpatient Center at Sunset Hills, Sunset Hills, Missouri

Gundersen Lutheran Medical Center, La Crosse, Wisconsin

Centro Comprensivo de Cancer de UPR, San Juan, Not set

San Juan City Hospital, San Juan, Not set

Conditions: Myelodysplastic Syndrome

Register for Updates

Learn More ›

A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

NCT06742281

Recruiting

The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 10016 healthy participants.

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

04/22/2025

Locations: Pinnacle Research Group, LLC, Anniston, Alabama +54 locations

Pinnacle Research Group, LLC, Anniston, Alabama

Velocity Clinical Research, Phoenix, Phoenix, Arizona

Velocity Clinical Research, Chula Vista, Chula Vista, California

Velocity Clinical Research, San Diego, La Mesa, California

Imax Clinical Trials, La Palma, California

Artemis Institute for Clinical Research, Riverside, California

Clinical Innovations Inc. dba CITrials, Riverside, California

Avacare, Sacramento, California

Collaborative Neuroscience Research, LLC, Torrance, California

Velocity Clinical Research, Washington DC, Washington, District of Columbia

Velocity Clinical Research, Hallandale Beach, Hallandale Beach, Florida

Homestead Associates in Research, Inc, Homestead, Florida

Biscayne Clinical Research, North Miami Beach, Florida

Headlands Research Orlando, Orlando, Florida

Best Choice Medical and Research Service, Pembroke Pines, Florida

Forcare Clinical Research, Tampa, Florida

Guardian Angel Research Center, Tampa, Florida

Lifeline Primary Care/Avacare, Lilburn, Georgia

Velocity Clinical Research, Savannah, Savannah, Georgia

Clinical Research Atlanta, Stockbridge, Georgia

Velocity Clinical Research, Boise, Meridian, Idaho

Velocity Clinical Research, Sioux City, Sioux City, Iowa

Velocity Clinical Research, Covington, Covington, Louisiana

Velocity Clinical Research, Lafayette, Lafayette, Louisiana

Velocity Clinical Research, New Orleans, New Orleans, Louisiana

CBH Health, Gaithersburg, Maryland

Advanced Primary and Geriatric Care/Avacare, Rockville, Maryland

Velocity Clinical Research, Rockville, Rockville, Maryland

DM Clinical Research, Southfield, Michigan

Velocity Clinical Research - Norfolk, Norfolk, Nebraska

Quality Clinical Research, Inc, Omaha, Nebraska

Velocity Clinical Research, Omaha, Omaha, Nebraska

DM Clinical Research, Jersey City, New Jersey

Velocity Clinical Research, Binghamton, Binghamton, New York

Rochester Clinical Research, Rochester, New York

Trial Management Associates, LLC, Wilmington, North Carolina

Velocity Clinical Research, Cleveland, Beachwood, Ohio

Velocity Clinical Research, Mt. Auburn, Cincinnati, Ohio

Velocity Clinical Research, Springdale, Cincinnati, Ohio

Tekton Research, LLC, Yukon, Oklahoma

DM Clinical Research, Philadelphia, Pennsylvania

Velocity Clinical Research, Anderson, Anderson, South Carolina

Velocity Clinical Research Gaffney, Gaffney, South Carolina

Avacare, Austin, Texas

Tekton Research, LLC, Austin, Texas

Velocity Clinical Research, Austin, Austin, Texas

Pan American Clinical Research, LLC, Brownsville, Texas

Avacare, Fort Worth, Texas

DM Clinical Research, Houston, Texas

Avacare, San Angelo, Texas

Tekton Research, LLC, San Antonio, Texas

Velocity Clinical Research, Salt Lake City, West Jordan, Utah

Clinical Research Partners LLC, Richmond, Virginia

Velocity Clinical Research, Suffolk, Suffolk, Virginia

Conditions: COVID-19

Register for Updates

Learn More ›

A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors

NCT06914128

Recruiting

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to check if BAY 3713372 is safe for further testing and find the dose that could be used to treat different cancer types that are also MTAP-deleted in future s... Read More

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to check if BAY 3713372 is safe for further testing and find the dose that could be used to treat different cancer types that are also MTAP-deleted in future studies. For this, the researchers will study and analyze: * the number of participants who have adverse events after receiving different doses of BAY 3713372 and their severity. * the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, their severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose. * the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses. * the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses. Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse. The study participants will receive BAY 3713372 (starting from low to high doses) in the study, to find the highest safe dose for further testing. Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems. Participants will visit the study site: * at least twice before the treatment starts * multiple times when they start taking the treatment * once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason During the study, the doctors and their study team will: * check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram * check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan * take tumor samples The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/22/2025

Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +11 locations

Conditions: MTAP-deleted Solid Tumors

Register for Updates

Learn More ›

Study of the Disease Process of Lymphangioleiomyomatosis

NCT00001465

Recruiting

Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor. This study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy. Researchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals. ...

Gender:

ALL

Ages:

Between 16 years and 100 years

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lung Disease, Pneumothorax, Tuberous Sclerosis, Lymphangioleiomyomatosis

Register for Updates

Learn More ›

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT00050752

Recruiting

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try t... Read More

This study will investigate what causes hereditary leiomyomatosis renal (kidney) cell cancer, or HLRCC, and how the disease is related to the development of kidney tumors. Leiomyomas are benign (non-cancerous) tumors arising from smooth muscle. HLRCC can cause various health problems. Some people develop red bumps on their skin that can be painful at times. Some women with HLRCC can develop leiomyomas of the uterus. In some families, people with HLRCC develop kidney tumors. This study will try to determine: * What gene changes (mutations) cause HLRCC * What kind of kidney tumors develop in HLRCC and how they grow * What the chance is that a person with HLRCC will develop a kidney tumor People with known or suspected HLRCC (and their family members of any age) may be eligible for this study. This includes people in families in which one or more members has skin leiomyoma and kidney cancer; skin leiomyoma and uterine leiomyoma; multiple skin leiomyomas; kidney cancer and uterine leiomyomas, or kidney cancer consistent with HLRCC, including, but not limited to, collecting duct or papillary, type II. Candidates will be screened with a physical examination, family history, and, for affected family members, a review of medical records, including pathology slides and computed tomography (CT) or magnetic resonance imaging (MRI) scans. Participants will undergo tests and procedures that may include the following: * Review of medical records, x-rays, and tissue slides * Physical examination and family history * Skin examination * Gynecological examination for women * Interviews with a cancer doctor, cancer nurses, kidney surgeon, and genetic counselor * Blood tests for: 1. Genetic research to identify the gene responsible for HLRCC 2. Evaluation of liver, kidney, heart, pancreas, and thyroid function 3. Complete blood count and clotting profile 4. Pregnancy test for pre-menopausal women 5. PSA test for prostate cancer in men over age 40 * CT or MRI scans (for participants 15 years of age and older only) * Skin biopsy (surgical removal of a small sample of skin tissue) * Cheek swab or mouth rinse to collect cells for genetic analysis * Medical photographs of lesions * Questionnaire When the tests are completed, participants will discuss the results with a doctor and possibly a genetic nurse or genetic counselor. The genetic findings will not be revealed to participants because their meaning and implications may not yet be understood. Participants may be asked to return to NIH from every 3 months to every 3 years, depending on their condition, for follow-up examinations and tests. ... Read Less

Gender:

ALL

Ages:

2 years and above

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Renal Tumor Histology, Cutaneous Leiomyoma, Kidney Cancer

Register for Updates

Learn More ›

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

NCT00342589

Recruiting

This study will examine the effectiveness of a new laboratory method for detecting pneumocystis organisms in a salt-water (saline) oral wash. Pneumocystis infection in people with weakened immunity especially patients with HIV infection or cancer, organ transplant recipients and people receiving immune suppressing therapy can cause life-threatening pneumonia. Currently, pneumocystis infection is diagnosed by sputum analysis or bronchoalveolar lavage. For the sputum analysis, patients are induced... Read More

This study will examine the effectiveness of a new laboratory method for detecting pneumocystis organisms in a salt-water (saline) oral wash. Pneumocystis infection in people with weakened immunity especially patients with HIV infection or cancer, organ transplant recipients and people receiving immune suppressing therapy can cause life-threatening pneumonia. Currently, pneumocystis infection is diagnosed by sputum analysis or bronchoalveolar lavage. For the sputum analysis, patients are induced to produce a sputum sample (liquid discharge from the lung) using a saline mist; however, many hospitals lack the expertise to perform this procedure. The second method, bronchoalveolar lavage, involves inserting a flexible tube into the lung and injecting saline to produce a specimen for diagnosis. This method, however, is time-consuming and can be uncomfortable. New techniques may allow the use of an oral wash to diagnose pneumocystis, even though an oral sample contains far fewer organisms than are obtained with the current methods. This study will examine whether new techniques, such as nucleic acid amplification, may enable a simple oral wash to be used effectively for diagnosis of pneumocystis infection. Patients 3 years of age and older with weakened immunity who have acute pneumonia may be eligible for this study. In addition, people at increased risk of infection with pneumocystis, including health care professionals, family members of patients, and other patients in health care facilities, may participate. Participants will have a medical history and review of medical records to determine their health status and determine if they have had recent respiratory problems or documented PCP. They will then provide an oral wash sample. For this procedure, subjects first rinse their mouth well. Then, they vigorously swish 50 milliliters of saline for 5 to 10 seconds and immediately repeat the procedure to provide two specimens. Washes may be requested daily, weekly, monthly, or for a period of time to be specified. Participants will also have two tubes of blood drawn (total of 20 milliliters, or 4 teaspoons) to test for evidence of pneumocystis. Although no other tests are required for this protocol, participants may be asked to provide optional add'l samples, as follows: If a sputum or bronchoalveolar lavage sample is required in the course of the patient s clinical mgmt, enough material will be obtained, if possible, for research purposes as well as what is needed for routine care. An induced sputum sample may be requested just for this protocol. For this procedure, a mask with a saline mist is placed over the face, inducing a cough that, it is hoped, will produce sputum from the lungs.... Read Less

Gender:

ALL

Ages:

Between 3 years and 99 years

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses

Register for Updates

Learn More ›

VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older

NCT01132859

Recruiting

Background: - The Vaccine Research Center (VRC) is dedicated to understanding immune responses associated with prevention and treatment of infectious diseases. To study these immune responses, researchers need to collect specimens and images from individuals who have recently had a vaccination or recovered from an infection. These specimens and images are used to study different diseases and immune responses, and can be used to investigate ways to prevent or treat different medical conditions.... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Immunity, Mucosal, Immune System Processes, Blood Specimen Collection

Register for Updates

Learn More ›

Evaluating New Radiation Techniques for Cardiovascular Imaging

NCT01621594

Recruiting

Title: Evaluating New Radiation Techniques for Cardiovascular Imaging Background: - Imaging studies such as computed tomography (CT) scans involve the use of radiation to create the pictures. Heart and blood vessel CT scans can cause high radiation exposure. Different methods of creating CT pictures have been developed to reduce the radiation dose. Researchers want to see how effective these new methods are in producing accurate CT scans. Objectives: - To study new ways of taking pictures of... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Coronary Disease

Register for Updates

Learn More ›

Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

NCT02535702

Recruiting

Background: Abusing alcohol, drugs, and other substances can cause serious health problems. These substances also can affect brain function. Researchers want to learn more about brain function by using magnetic resonance imaging (MRI). This uses a magnetic field and radio waves to take pictures of the brain. Objective: To develop new ways to use MRI to study the brain. Eligibility: Healthy people 18 years of age or older. Design: Participants will be screened with a medical history, physi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/22/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Normal Physiology

Register for Updates

Learn More ›

Taste Bud-Derived Stem Cells in Humans

NCT03366168

Recruiting

Background: Stem cells are found in body tissues. They can regenerate into more of the same cells or become other types of cell. Researchers want to use stem cells from taste buds to try to make cells that secrete insulin. Taste buds are found mostly on the tip and sides of the tongue. Researchers also want to study if the number of taste buds and stem cells decrease as people age. They will remove small pieces of tongue tissue (about the size of a pen tip). The taste buds will grow back. It is... Read More

Gender:

ALL

Ages:

Between 18 years and 120 years

Trial Updated:

04/22/2025

Locations: National Institute of Aging, Clinical Research Unit, Baltimore, Maryland

Conditions: Diabetes

Register for Updates

Learn More ›

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

NCT03889912

Recruiting

This study is researching an experimental drug called cemiplimab. The study is focused on Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC). The aim of the study is to evaluate the safety and tolerability (how your body reacts to the drug) of cemiplimab (also known as REGN2810). The first part of the study tested several different doses of cemiplimab given weekly for 12 weeks. The study is also looking at several other research questions, including: * What side effects... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/22/2025

Locations: Medical Dermatology Specialists, Phoenix, Arizona +21 locations

Conditions: Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma

Register for Updates

Learn More ›

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

NCT04576117

Recruiting

This phase III trial investigates the best dose of vinblastine in combination with selumetinib and the benefit of adding vinblastine to selumetinib compared to selumetinib alone in treating children and young adults with low-grade glioma (a common type of brain cancer) that has come back after prior treatment (recurrent) or does not respond to therapy (progressive). Selumetinib is a drug that works by blocking a protein that lets tumor cells grow without stopping. Vinblastine blocks cell growth... Read More

Gender:

ALL

Ages:

Between 2 years and 25 years

Trial Updated:

04/22/2025

Locations: Children's Hospital of Alabama, Birmingham, Alabama +99 locations

Children's Hospital of Alabama, Birmingham, Alabama

Arkansas Children's Hospital, Little Rock, Arkansas

Loma Linda University Medical Center, Loma Linda, California

Children's Hospital Los Angeles, Los Angeles, California

Kaiser Permanente-Oakland, Oakland, California

Children's Hospital of Orange County, Orange, California

Lucile Packard Children's Hospital Stanford University, Palo Alto, California

Children's Hospital Colorado, Aurora, Colorado

Connecticut Children's Medical Center, Hartford, Connecticut

Yale University, New Haven, Connecticut

Alfred I duPont Hospital for Children, Wilmington, Delaware

Children's National Medical Center, Washington, District of Columbia

University of Florida Health Science Center - Gainesville, Gainesville, Florida

Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida

Nemours Children's Clinic-Jacksonville, Jacksonville, Florida

Arnold Palmer Hospital for Children, Orlando, Florida

Nemours Children's Hospital, Orlando, Florida

Johns Hopkins All Children's Hospital, Saint Petersburg, Florida

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida

Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Lurie Children's Hospital-Chicago, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Riley Hospital for Children, Indianapolis, Indiana

Ascension Saint Vincent Indianapolis Hospital, Indianapolis, Indiana

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

Norton Children's Hospital, Louisville, Kentucky

Children's Hospital New Orleans, New Orleans, Louisiana

Maine Children's Cancer Program, Scarborough, Maine

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

Walter Reed National Military Medical Center, Bethesda, Maryland

Dana-Farber Cancer Institute, Boston, Massachusetts

C S Mott Children's Hospital, Ann Arbor, Michigan

Children's Hospital of Michigan, Detroit, Michigan

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan

Corewell Health Children's, Royal Oak, Michigan

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota

Mayo Clinic in Rochester, Rochester, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Children's Mercy Hospitals and Clinics, Kansas City, Missouri

Cardinal Glennon Children's Medical Center, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Children's Hospital and Medical Center of Omaha, Omaha, Nebraska

University of Nebraska Medical Center, Omaha, Nebraska

Morristown Medical Center, Morristown, New Jersey

Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey

University of New Mexico Cancer Center, Albuquerque, New Mexico

Albany Medical Center, Albany, New York

Roswell Park Cancer Institute, Buffalo, New York

The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

State University of New York Upstate Medical University, Syracuse, New York

New York Medical College, Valhalla, New York

Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina

Duke University Medical Center, Durham, North Carolina

East Carolina University, Greenville, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Sanford Broadway Medical Center, Fargo, North Dakota

Children's Hospital Medical Center of Akron, Akron, Ohio

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Nationwide Children's Hospital, Columbus, Ohio

Dayton Children's Hospital, Dayton, Ohio

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Oregon Health and Science University, Portland, Oregon

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Saint Christopher's Hospital for Children, Philadelphia, Pennsylvania

Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania

Prisma Health Richland Hospital, Columbia, South Carolina

BI-LO Charities Children's Cancer Center, Greenville, South Carolina

East Tennessee Childrens Hospital, Knoxville, Tennessee

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Dell Children's Medical Center of Central Texas, Austin, Texas

UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas

Cook Children's Medical Center, Fort Worth, Texas

Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas

M D Anderson Cancer Center, Houston, Texas

Children's Hospital of San Antonio, San Antonio, Texas

University of Texas Health Science Center at San Antonio, San Antonio, Texas

Primary Children's Hospital, Salt Lake City, Utah

Children's Hospital of The King's Daughters, Norfolk, Virginia

Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia

Seattle Children's Hospital, Seattle, Washington

Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington

Madigan Army Medical Center, Tacoma, Washington

West Virginia University Healthcare, Morgantown, West Virginia

University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin

Children's Hospital of Wisconsin, Milwaukee, Wisconsin

University of Alberta Hospital, Edmonton, Alberta

British Columbia Children's Hospital, Vancouver, British Columbia

CancerCare Manitoba, Winnipeg, Manitoba

IWK Health Centre, Halifax, Nova Scotia

Children's Hospital of Eastern Ontario, Ottawa, Ontario

Hospital for Sick Children, Toronto, Ontario

The Montreal Children's Hospital of the MUHC, Montreal, Quebec

Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec

Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec

CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Not set

Conditions: Recurrent Low Grade Astrocytoma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Recurrent WHO Grade 2 Glioma, Refractory WHO Grade 1 Glioma

Register for Updates

Learn More ›

All Clinical Trials

Match to Clinical Trials